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Low T3Cardiologists will think it just that thyroid dysfunction would
be associated with many cardiovascular diseases [1–3]. In
particular, adverse effects of low free triiodothyronine (fT3) level
in cardiovascular diseases have already been reported [3–5].
However, among the cardiovascular diseases, previous reports
have demonstrated that chronic heart failure and thyroid function
are not consistently associated [4–9]. Thyroid stimulating hor-
mone (TSH) did not show consistent prognostic value in chronic
heart failure [7,8]. Moreover, there is no previous report clearly
indicating the signiﬁcant importance of thyroid function in the
treatment of acute decompensated heart failure (ADHF). Consid-
ering such an insufﬁcient state, at ﬁrst, it is necessary to assess
whether we could separate the adverse outcome of ADHF patients
by thyroid function on admission or not.
In this issue of the Journal of Cardiology [10], Okayama et al.
investigated the association between thyroid hormone levels [TSH,
fT3, and free thyroxine (fT4)] and outcome in 270 patients
hospitalized for ADHF. Receiver operating characteristics (ROC)
curve analysis revealed the most favorable performance of fT3
(area under the ROC curve: 0.791, sensitivity 85.0%, speciﬁcity
72.0%). Interestingly, multivariate analysis indicated that low fT3
level was independently associated with higher in-hospital
mortality (odds ratio 14.4). The probability of 1-year total death
among patients with low fT3 was signiﬁcantly higher than that
among patients with normal fT3. These results are suggestive and
provide meaningful clinical implications. The authors have special
knowledge in clinical studies and the treatment for heart failure in
a major Japanese cardiovascular center, and the present study
design, aim, and statistic analysis are reasonable and organized.
Considering the present results, as concluded by the authors, we
also say with conviction that low fT3 level was associated with
adverse outcomes in patients hospitalized for ADHF, and that fT3
measurements should be done for the risk stratiﬁcation of ADHFDOI of original article: http://dx.doi.org/10.1016/j.jjcc.2015.04.006
http://dx.doi.org/10.1016/j.jjcc.2015.05.001
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightspatients. Furthermore, it is suggestive that the prognostic value in
ADHF patients is superior in fT3 than in TSH, because thyroid
hormone action in the myocardium is via speciﬁc T3 receptors, and
low fT3 levels may worsen contractility, increase susceptibility to
arrhythmias, and contribute to mortality in patients with heart
failure despite normal T4 and TSH levels [14].
We should discuss whether low fT3 level is a target or severity
marker of ADHF. Low fT3 levels must induce heart failure, because
thyroid hormones affect various organs and cells and are
associated with maintenance of normal cardiac function
[1–9,11,12]. Actually, low fT3 was associated with pulmonary
capillary wedge pressures, and lower ejection fraction [2]. Previous
studies have demonstrated that fT3 increases tissue thermogene-
sis, cardiac contractility, heart rate, and cardiac output, and
decreases systemic vascular resistance including that of the
coronary artery [1,12,13]. Considering these results, low fT3
would be a therapeutic target of ADHF, and a previous clinical
study has demonstrated the beneﬁts of short-term T3 replacement
on advanced heart failure [15]. However, we are afraid that long-
term T3 replacement could cause unexpected inotropic effects, and
we should determine the causal importance of hypothyroidism in
ADHF patients, because the proportion of hypothyroidism in
pathophysiology is not uniform and has dynamic features. In
addition, hypothyroidism is also induced by various systemic
organ damages in heart failure. As discussed by the authors,
cachexia and/or poor nutritional status have recently been focused
on as topics in heart failure, and these topics are strongly mediated
by hypothyroidism, especially low fT3 levels. Although the present
paper could not conclude whether thyroid function is the target or
a severity marker of ADHF, cardiologists had better consider low
fT3 levels, at least, as a useful clinical marker of severity and risk
stratiﬁcation in ADHF patients.
As the authors already acknowledge, the present paper is a
single-center observational study with a limited number of study
patients, and the measurement of thyroid hormone was not
performed in all ADHF patients. Considering these study limita-
tions, the present paper could not provide data on the prevalence
and prognostic impact of persisting thyroid function abnormality
on ADHF patients. To strengthen the authors’ concept, time course
of low fT3 levels in ADHF patients and more detailed assessment of
ADHF (echocardiographic, hemodynamic, and exercise tolerance
test) are expected in the future following studies. However, the
present authors’ clinical message is suggestive, and we should
focus on low fT3, not TSH, in ADHF patients more and more. reserved.
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